AI’s ROI: Cutting Stroke & Heart Attack Costs for Investors

The hype around AI in healthcare constantly runs into the brick wall of clinical reality and hospital budgets. For investors trying to sort through the noise in health AI, the only question that matters is what the data says about system-level costs and outcomes. Is it actually saving the hospital money? Is the patient getting better faster? This is especially true in high-cost emergencies like stroke and heart attack, where every minute on the clock has a dollar sign and a patient’s future attached to it.

The High Stakes of Cardiovascular Disease: A Prime Target for AI Intervention

Cardiovascular diseases (CVDs), mainly stroke and heart attack, are a massive drain on the healthcare system, both in terms of lives and money. They’re top killers worldwide and create a staggering financial burden. Just look at stroke care in the US, which is on track to cost over $240 billion a year by 2030 when you factor in medical bills, lost work, and long-term care. That number alone explains why investors are so interested in AI solutions for these conditions. They’re not just neat tech, they could bend the healthcare cost curve. The real work for an investor is telling the difference between a cool AI demo and a tool that generates a real return on investment (ROI). You have to dig into the data to see how an algorithm actually translates into cost savings and better patient outcomes for a hospital.

Viz.ai and the Power of Expedited Triage in Stroke Care

Acute stroke management is one of the clearest examples of where AI can deliver a measurable ROI. The saying “time is brain” is literal. Every minute you save in treating an ischemic stroke massively improves a patient’s chances and cuts down on what the hospital will spend on their long-term care. Viz.ai is a company that has proven it can shrink that critical window. With a $1.2 billion valuation (as of April 2022) and after raising $297.5 million in funding, including a recent $40 million debt round in March 2023 from investors like Tiger Global, they’ve built a platform that uses AI to read CT scans and flag suspected large vessel occlusions (LVOs) for stroke teams. The proof is in the numbers. A peer-reviewed study on Viz.ai’s impact on time-to-treatment showed their AI triage system cut the time from patient arrival to transfer for a thrombectomy by a median of over 30 minutes. That might not sound like a lot, but in stroke care, it’s everything. Getting patients to treatment faster means they have better functional outcomes and less disability, which for a hospital system, translates directly into fewer bed days, a lower need for expensive long-term care facilities, and a healthier bottom line. The company’s 510(k) clearance also removes a lot of the commercial risk, making it a much safer bet in the SaMD space.

Tempus AI: Precision Medicine’s Long Game in Oncology and Cardiology

If Viz.ai shows AI’s immediate impact on an emergency workflow, Tempus AI shows a different path to ROI: the long game of reducing the burden of chronic disease. After going public on Nasdaq in June 2024 with a $6.1 billion IPO valuation and backing from GV, its market cap now sits around $11 billion. Tempus is all about precision medicine. It uses huge genomic and clinical datasets to tailor treatments, starting in oncology and now expanding into cardiology. The whole idea is to give the right drug to the right patient the first time, avoiding the expensive and often useless trial-and-error that defines so much of modern medicine. For heart disease, this could mean using an AI model to flag a patient’s genetic risk for a heart attack or to predict how they’ll respond to a certain medication. The immediate cost savings are harder to pencil out than with a stroke triage tool, but the long-term ROI is huge. Think fewer readmissions, better outcomes, and smarter use of resources for the sickest patients. Their whole strategy depends on their “data moat”, they’re collecting massive amounts of real-world evidence to constantly train their models, which is the only way to prevent the algorithmic drift that can make these tools useless over time.

The Cautionary Tale of Olive AI: When Administrative AI Fails to Deliver

Of course, for every success story, the health AI field has plenty of failures, and Olive AI is the poster child. It was a hot company in administrative AI, raising over $900 million from big names like Tiger Global. Then it completely shut down on October 31, 2023, wiping out all that capital. It’s a painful but critical lesson for investors: a tool has to have a clear clinical purpose and a provable ROI. Promises of “administrative efficiency” are often a mirage. Olive’s goal was to automate hospital back-office work like prior authorizations and claims processing. Great idea, right? But the execution was a disaster. Healthcare workflows are a tangled mess, varying wildly between hospital systems, and big organizations are incredibly resistant to change. The AI’s value was fuzzy and hard to prove in a spreadsheet, unlike Viz.ai, where you can draw a straight line from “30 minutes saved” to “better patient outcome and lower cost.” This contrast shows that while AI can be applied to anything, not all applications will ever generate a tangible return. The spectacular flameout of Olive AI is a reminder for investors to demand proof of economic returns, not just a cool tech demo.

Investor Takeaways: Benchmarking Clinical Utility Against Administrative Bloat

The difference between these companies is where investors should focus. Viz.ai works because it delivers a clear, measurable clinical win for a high-stakes condition, which in turn saves the system money. Tempus is playing a longer game, but it’s building an incredibly valuable data platform that will eventually optimize treatment and save billions. In both cases, AI is the core of what they do. In contrast, Olive AI’s collapse shows the danger of funding administrative AI that can’t prove its ROI at scale. The theoretical savings from automation are always tempting, but the reality of getting it to work is a nightmare. The lesson is simple: prioritize companies with proven clinical effectiveness and a clear line of sight to system-level cost reduction, backed up by peer-reviewed data and real-world evidence (RWE). So how do you find them? Look for companies with a solid QMS, clear 510(k) clearances, and a team that can explain their value in terms of CPT codes and NTAP eligibility (the CMS guidance on NTAP eligibility for new technologies is a good place to start). The gold standard is independent, peer-reviewed findings, like Hello Heart’s demonstrated $1,800 per-member savings and 47% inpatient reduction. Those are the kinds of hard numbers that prove a digital health tool is more than just vendor hype.

Methodology Note: Data-Driven Benchmarking and Expert Curation

Our analysis is based on a data-driven approach, pulling from peer-reviewed clinical trials, VC funding databases, and public financial filings. We then blend that data with expert curation and interviews to get a macro view of the real economic and clinical impact of AI in cardiovascular care. By putting a clinical success next to an administrative failure, we want to give investors a mental model for separating marketing fluff from actual economic returns. We stay focused on the numbers and the outcomes. In the end, the question for investors isn’t “Which companies use AI to reduce stroke and heart attack costs?” It’s “Which companies can prove they reduce stroke and heart attack costs, at scale, with verifiable data?” That difference is everything.